Evidence map›Paper›PMID 40346555›Full record

ArticleCardiovascular diabetology2025

Life's Essential 8 cardiovascular health, cardiovascular-kidney-metabolic syndrome stages, and incident cardiovascular events: a nationwide 10-year prospective cohort study in China.

Mian Li, Min Xu, Yi Ding, Hong Lin, Guijun Qin, Tiange Wang, Yu Xu, Yuhong Chen, Shuangyuan Wang, Zhiyun Zhao and 35 more

Abstract read
In one paragraph

Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

Mian Li *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
Min Xu *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
Yi Ding *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
Hong Lin *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
Guijun Qin *The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Tiange Wang *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
Yu XuDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
Yuhong ChenDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
Shuangyuan WangDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
Zhiyun ZhaoDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
Jie ZhengDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
Li YanSun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Lixin ShiAffiliated Hospital of Guiyang Medical College, Guiyang, China.
Zhengnan GaoDalian Municipal Central Hospital, Dalian, China.
Lulu ChenUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Tianshu ZengUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ruying HuZhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Zhen YeZhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Xuefeng YuTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Gang ChenFujian Provincial Hospital, Fujian Medical University, Fuzhou, China.
Qing SuXinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yiming MuChinese people's Liberation Army General Hospital, Beijing, China.
Xulei TangThe First Hospital of Lanzhou University, Lanzhou, China.
Qin WanThe Affiliated Hospital of Southwest Medical University, Luzhou, China.
Guixia WangThe First Hospital of Jilin University, Changchun, China.
Feixia ShenThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xuejiang GuThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Zuojie LuoThe First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yingfen QinThe First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Li ChenQilu Hospital of Shandong University, Jinan, China.
Xinguo HouQilu Hospital of Shandong University, Jinan, China.
Yanan HuoJiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang, China.
Qiang LiThe Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Hong QiaoThe Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Yinfei ZhangCentral Hospital of Shanghai Jiading District, Shanghai, China.
Chao LiuJiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China.
Youmin WangThe First Affiliated Hospital of Anhui Medical University, Hefei, China.
Shengli WuKaramay Municipal People's Hospital, Karamay, Xinjiang, China.
Tao YangThe First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Huacong DengThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jiajun ZhaoShandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Guang NingDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
Jieli LuDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China. jielilu@hotmail.com.ORCID 0000-0003-1317-0896
Weiqing WangDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China. wqingw61@163.com.ORCID 0000-0001-6027-3084
Yufang BiDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China. byf10784@rjh.com.cn.ORCID 0000-0002-4829-5915

Funding

National Key Research and Development Program of China 2022ZD0162102Science and Technology Commission of Shanghai Municipality 24DZ2307200Shanghai Municipal People's Government 22Y31900300
6 · The paper itself

Abstract

backgroundDefinition and staging rationale of cardiovascular-kidney-metabolic syndrome were developed. The utility of cardiovascular-kidney-metabolic construct in risk stratification and target strategies of health and behavior modifications needs to be addressed. The study aims to investigate the individual and combined associations of cardiovascular-kidney-metabolic stage and cardiovascular health (CVH) by Life's Essential 8 (LE 8) with incident cardiovascular events (CVD), and determine the distribution and contribution of domain-specific CVH across cardiovascular-kidney-metabolic stages.

methodsThe study included 100,727 individuals in the China Cardiovascular Disease and Cancer Cohort with complete data on cardiovascular-kidney-metabolic factors and LE 8 metrics, with a median follow-up of 10.1 years. Cardiovascular-kidney-metabolic stages and CVH metrics (nicotine exposure, diet, physical activity, sleep, body mass index, blood lipids, blood pressure, blood glucose) were defined according to Presidential Advisory from the American Heart Association. Incident CVD events including cardiovascular death, myocardial infarction, and stroke were validated. The Fine-Gray hazard model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of CKM stages or CVH status associated with CVD.

resultsCompared with cardiovascular-kidney-metabolic stage 0, the adjusted competing HRs and 95% CIs of CVD events were 1.20 (0.95-1.51), 2.45 (1.97-3.04), 4.43 (3.53-5.58), and 5.95 (4.75-7.45) from stage 1 to stage 4, respectively. Optimal CVH status and each optimal CVH metric presented a significantly decreased risk of CVD events. Variation was observed in the association between cardiovascular-kidney-metabolic stage and CVD events with different CVH status or numbers of optimal CVH metrics. Compared with those in stage 0, Participants in stage 1 or 2 with optimal CVH no longer had elevated risks for incident CVD events. Suboptimal health factor contributed larger population attributable fractions to CVD events in cardiovascular-kidney-metabolic stage 0-2 (51.2%) than in stage 3-4 (25.2%), whereas suboptimal health behavior exhibited larger contribution in advanced stages (13.1% in stage 0-2 and 18.2% in stage 3-4).

conclusionsThe study indicated that cardiovascular-kidney-metabolic stage was associated with cardiovascular events, and optimal cardiovascular health could attenuate this risk. Health factor contributed predominantly at the early-stage, whereas health behavior exhibited consistent and slightly increased contribution along the spectrum. These findings support the utility of cardiovascular-kidney-metabolic construct and highlight the importance of target health improvement based on LE 8 framework.

Indexed as

Cardio-Renal SyndromeCardiovascular DiseasesMetabolic SyndromeAdultAgedBiomarkersChinaFemaleHealth StatusHeart Disease Risk FactorsHumansIncidenceMaleMiddle AgedPrognosisProspective StudiesBiomarkersCardiovascular eventsCardiovascular healthCardiovascular-kidney-metabolic syndromeHealth behaviorHealth factor

Identifiers

PMID40346555
PMCPMC12065188

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.